Compare
Kura Oncology, Inc. vs Spero Therapeutics, Inc. vs Rockwell Medical, Inc. vs Enanta Pharmaceuticals Inc
| Latest fiscal year | Kura Oncology, Inc. KURA | Spero Therapeutics, Inc. SPRO | Rockwell Medical, Inc. RMTI | Enanta Pharmaceuticals Inc ENTA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-09-30 |
| Revenue | $67.48M | $66.80M | $69.26M | $65.32M |
| Revenue growth (YoY) | +25.2% | +39.2% | -31.8% | -3.4% |
| Gross margin | n/a | n/a | 16.9% | n/a |
| Operating margin | -449.9% | 9.5% | -6.8% | -130.7% |
| Net margin | -412.9% | 12.8% | -7.7% | -125.4% |
| Net income | -$278.67M | $8.57M | -$5.31M | -$81.89M |
| EPS (Diluted) | -$3.18 | $0.15 | -$0.15 | -$3.84 |
| Operating cash flow | -$64.06M | -$12.62M | -$659.0K | -$19.27M |
| Free cash flow | -$70.70M | n/a | -$1.20M | -$32.17M |
| Cash & equivalents | $149.10M | $40.27M | $10.71M | $32.30M |
| Total assets | $738.36M | $68.92M | $57.15M | $280.73M |
| Total liabilities | $564.23M | $9.90M | $20.16M | $216.01M |
| Shareholders' equity | $174.13M | $59.02M | $36.98M | $64.72M |
| Return on year-end equity | -160.0% | 14.5% | -14.4% | -126.5% |
| Shares outstanding | 87.86M | 56.41M | 39.41M | 21.39M |
Revenue, most recent five fiscal years
| Fiscal year | Kura Oncology, Inc. | Spero Therapeutics, Inc. | Rockwell Medical, Inc. | Enanta Pharmaceuticals Inc |
|---|---|---|---|---|
| Latest | $67.48M Ended 2025-12-31 | $66.80M Ended 2025-12-31 | $69.26M Ended 2025-12-31 | $65.32M Ended 2025-09-30 |
| 1 year earlier | $53.88M Ended 2024-12-31 | $47.98M Ended 2024-12-31 | $101.49M Ended 2024-12-31 | $67.64M Ended 2024-09-30 |
| 2 years earlier | $0 Ended 2023-12-31 | $103.78M Ended 2023-12-31 | $83.61M Ended 2023-12-31 | $79.20M Ended 2023-09-30 |
| 3 years earlier | n/a | $53.51M Ended 2022-12-31 | $72.81M Ended 2022-12-31 | $86.16M Ended 2022-09-30 |
| 4 years earlier | n/a | $18.26M Ended 2021-12-31 | $61.93M Ended 2021-12-31 | $97.07M Ended 2021-09-30 |